Paclitaxel
Paclitaxel is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Paclitaxel; Generic name: PACLITAXEL; Drug class: Microtubule Inhibitor [EPC].
| Brand name | Paclitaxel |
|---|---|
| Generic name | PACLITAXEL |
| Drug class | Microtubule Inhibitor [EPC] |
| Manufacturer | Sandoz Inc |
| Used for | 1 INDICATIONS AND USAGE Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. (1.1) Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. (1.2) Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine. (1.3) 1.1 Metastatic Breast Cancer Paclitaxel protein-bound particles for injectable suspension (albumin-bound) is indicated for th |
| Dosage | 2 DOSAGE AND ADMINISTRATION Do not substitute paclitaxel protein-bound particles for injectable suspension (albumin-bound) for other paclitaxel products. (2.1) Extravasation: Closely monitor the infusion site for extravasation and infiltration. (2.1) Metastatic Breast Cancer (MBC): Recommended dosage of paclitaxel protein-bound particles for injectable suspension (albumin-bound) is 260 mg/m2 intravenously over 30 minutes every 3 weeks. (2.2) Non-Small Cell Lung Cancer (NSCLC): Recommended dosage |
| Warnings | WARNING: NEUTROPENIA Do not administer paclitaxel protein-bound particles for injectable suspension (albumin-bound) therapy to patients who have baseline neutrophil counts of less than 1,500 cells/mm 3 [see Contraindications (4) ]. Monitor for neutropenia, which may be severe and result in infection or sepsis, it is recommended that frequent [see Warnings and Precautions (5.1 , 5.3) ]. Perform frequent complete blood cell counts on all patients receiving paclitaxel protein-bound particles for in |
| Active ingredient(s) | PACLITAXEL |
| Route | INTRAVENOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15ca4829-8fee-45f9-b4bc-b31c15732cd6 |